A Novel Approach to Peptide Labeling for the Imaging of Cancer by PET
Tech ID: 19235 / UC Case 2004-498-0
New materials and methods that enable the simple inclusion of 18F into cancer-targeting peptides that can be used as radiolabels for PET imaging
Positron emission tomography (PET) is a highly sensitive, noninvasive method for the detection of cancer. Although the technique is generally available in major oncology clinics, its usefulness is nonetheless restricted by limitations in radiolabeling methodology. PET makes predominant use of the positron-emitting fluorine isotope 18F. Currently, the only practical vehicle for clinical application of 18F in PET is 2-18F-2-deoxy-D-glucose (FDG), which is taken up by many types of tumor cells. The exclusive use of FDG however limits the types of cancers which can be imaged by PET. Certain peptides and small proteins are known to be remarkably sensitive and selective cancer targeting agents. However, the labeling of these peptides with 18F is laborious and impractical in a clinical setting. This invention addresses the above obstacle directly by the attachment of a highly selective fluoride ion binding agent to cancer-specific peptides, allowing immediate radiolabeling with 18F. This eliminates the necessity to perform any synthetic chemistry with 18F, resulting in a highly simplified, automatable labeling protocol which has the potential to revolutionize the application of PET to the cancer problem.
The combination of disease-specific imaging with a highly simplified 18F labeling protocol.
- "Targeting Peptides and Positron Emission Tomography." H. Lundqvist, V. Tolmachev, Biopolymers 2002, 66, 381.
- "Therapeutic Cancer Targeting Peptides." O. H. Aina, T. C. Sroka, M.-L. Chen, K. S. Lam, Biopolymers (Peptide Science) 2002, 66, 184.
- "Somatostatin Analogs and Radiopeptides in Cancer Therapy." S. Froidevaux, A. N. Eberle, Biopolymers (Peptide Science) 2002, 66, 161.
- "Molecular Imaging of Cancer with Positron Emission Tomography." S. S. Gambhir, Nature Reviews Cancer 2002, 2, 683.
- "Positron Emission Tomography in Cancer Research and Treatment." M. Mandelkern, J. Raines, Technology in Cancer Research and Treatment 2002, 1, 423.
- "Precedent and Theory Unite in the Hypothesis of a Highly Selective Fluoride Receptor." M. Mascal, Angewandte Chemie International Edition 2006, 45, 2890.
- "Integrins in Cancer Treatment." J. A. Eble, J. Haier, Curr. Cancer Drug Targets 2006, 6, 89.
- "Fluoride-Selective Host Based on Anion-Pi Interactions, Ion Pairing, and Hydrogen Bonding: Synthesis and Fluoride-Ion Sandwich Complex." M. Mascal, I. Yakovlev, E.B. Nikitin, and J.C. Fettinger, Angewandte Chemie International Edition 2007, 46, 8782-4.
|United States Of America||Issued Patent||7,723,322||05/25/2010||2004-498|
- Mascal, Mark J.
cancer imaging, positron emission tomography, PET, cancer, PET imaging
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- Peptide Conjugates for Imaging and Treating Pancreatic Cancer
- An Effective Anti-Cancer Combination Therapy, with Substantially Reduced Side Effects
- Novel Small Molecule Biomarker For Detection Of Breast Cancer and its Risk
- Multiplexed Point-of-Care Breast Cancer Marker Detection System
- Identification of Cancer Biomarkers using Mammalian Chromatin Modifying Properties of Lunasin